BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it will be presenting at the 28th Annual Congress of the World Muscle Society, being held October 3-7 in Charleston, South Carolina. Details of the presentations can be found below:
28th Annual Congress of the World Muscle Society, being held October 3-7 in Charleston, South Carolina
Title: Phase 1 Study of PGN-EDO51 Demonstrates Tolerability, Delivery, and High Levels of Exon Skipping for Treatment of Duchenne Muscular Dystrophy (DMD)
Poster Number: P44
Location: Ballroom A-C
Date & Time: October 4th at 2:30-3:30pm EDT
Presenter: Michelle Mellion, M.D., Senior Vice President, Head of Clinical Development
Title: Single – and Repeat – Dose Nonclinical Data for PGN-EDO51 Demonstrate Potential for the Treatment of Duchenne Muscular Dystrophy (DMD)
Poster Number: P25
Location: Ballroom A-C
Date & Time: October 4th at 5:15-6:15pm EDT
Presenter: Ashling Holland, Ph.D., Director, Preclinical Development
Title: CONNECT-EDO51: Trial Designs to Support the Development of PGN-EDO51 for Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Poster Number: P26
Location: Ballroom A-C
Date & Time: October 4th at 5:15-6:15pm EDT
Presenter: Michelle Mellion, M.D., Senior Vice President, Head of Clinical Development
Title: Three Novel Enhanced Delivery Oligonucleotide Candidates for Duchenne Muscular Dystrophy Mediate High Levels of Exon 53, 45, and 44 Skipping
Poster Number: P27
Location: Ballroom A-C
Date ...